Detailed company information
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 27, 2026
Earnings Transcript for 2025 - Q4Released: Feb 26, 2026
Earnings Transcript for 2025 - Q3Released: Oct 29, 2025
Earnings Transcript for 2025 - Q2Released: Jul 31, 2025
Earnings Transcript for 2025 - Q1Released: Apr 30, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 07, 2024
Earnings Transcript for 2024 - Q1Released: May 07, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 06, 2023
Earnings Transcript for 2023 - Q2Released: Aug 04, 2023
Earnings Transcript for 2023 - Q1Released: May 03, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 04, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 29, 2021
Earnings Transcript for 2021 - Q1Released: Apr 28, 2021
Earnings Transcript for 2020 - Q4Released: Feb 18, 2021
Earnings Transcript for 2020 - Q3Released: Oct 29, 2020
Earnings Transcript for 2020 - Q2Released: Jul 30, 2020
OPKO Health is refining MDX2001's dose and regimen based on Phase Ia efficacy signals to select tumor cohorts for Phase Ib expansion, with formal data presentation expected in 2026.
Read post
Dafinchi
